Indication
Giant cell tumor of bone
Giant cell tumor of bone is a rare, benign primary osteolytic neoplasm characterized by local aggressiveness and marked bone destruction. Read more about Giant cell tumor of bone
8 drugs 8 manufacturers
Drugs that treat it
Common Giant cell tumor of bone therapies.
WYOST (denosumab-bbdz)
OSENVELT (denosumab-bmwo)
BOMYNTRA (denosumab-bnht)
BILPREVDA (denosumab-nxxp)
XTRENBO (denosumab-qbde)
AUKELSO (denosumab-kyqq)
JUBEREQ (denosumab-desu)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonGiant cell tumor of bone is a rare, benign primary osteolytic neoplasm characterized by local aggressiveness and marked bone destruction.
It predominantly affects young and middle-aged skeletally mature adults, most commonly presenting in the third and fourth decades of life with a slight female predominance.
Pathophysiologically, the tumor arises in the epiphyseal-metaphyseal regions of long bones—most frequently around the knee in the distal femur and proximal tibia—and is histopathologically defined by proliferating neoplastic mononuclear stromal cells that recruit numerous reactive, osteoclast-like multinucleated giant cells.
Although histologically nonmalignant, it frequently causes localized cortical thinning, pathological fractures, and joint pain, exhibiting a high potential for local recurrence and rare pulmonary metastasis.
- nih.gov
Giant cell tumor of bone is a rare, benign primary osteolytic neoplasm characterized by local aggressiveness and marked bone destruction Pathophysiologically, the tumor arises in the epiphyseal-metaphyseal regions of long bones—most frequently around the knee in the distal femur and proximal tibia—and is histopathologically defined by proliferating neoplastic mononuclear stromal cells that recruit numerous reactive, osteoclast-like multinucleated giant cells
- nih.gov
Giant cell tumor of bone is a rare, benign primary osteolytic neoplasm characterized by local aggressiveness and marked bone destruction
- nih.gov
It predominantly affects young and middle-aged skeletally mature adults, most commonly presenting in the third and fourth decades of life with a slight female predominance Pathophysiologically, the tumor arises in the epiphyseal-metaphyseal regions of long bones—most frequently around the knee in the distal femur and proximal tibia—and is histopathologically defined by proliferating neoplastic mononuclear stromal cells that recruit numerous reactive, osteoclast-like multinucleated giant cells
- sicot-j.org
It predominantly affects young and middle-aged skeletally mature adults, most commonly presenting in the third and fourth decades of life with a slight female predominance
- clevelandclinic.org
Pathophysiologically, the tumor arises in the epiphyseal-metaphyseal regions of long bones—most frequently around the knee in the distal femur and proximal tibia—and is histopathologically defined by proliferating neoplastic mononuclear stromal cells that recruit numerous reactive, osteoclast-like multinucleated giant cells Although histologically nonmalignant, it frequently causes localized cortical thinning, pathological fractures, and joint pain, exhibiting a high potential for local recurren...
- nih.gov
Although histologically nonmalignant, it frequently causes localized cortical thinning, pathological fractures, and joint pain, exhibiting a high potential for local recurrence and rare pulmonary metastasis
- childrenshospital.org
Although histologically nonmalignant, it frequently causes localized cortical thinning, pathological fractures, and joint pain, exhibiting a high potential for local recurrence and rare pulmonary metastasis
Personalize your experience
Follow Giant cell tumor of bone and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.